DuPont de Nemours vs Eastman Chemical
DD and EMN side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DD and EMN compare
DuPont de Nemours is the larger company, worth 2.5 times as much as Eastman Chemical ($19.0B against $7.6B).
On earnings, Eastman Chemical is cheaper: it trades at 12.2× trailing earnings, against 312× for DuPont de Nemours.
DuPont de Nemours grew revenue faster over the last twelve months (3.3% versus 0.27% for Eastman Chemical).
Eastman Chemical keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with 0.79% at DuPont de Nemours.
Both pay dividends: DuPont de Nemours yields 1.7% and Eastman Chemical 5.1%.
Eastman Chemical scores higher on the StockData Score (16 against 10 for DuPont de Nemours), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DD | EMN |
|---|---|---|
| Size and price | ||
| Market cap | $19.0B | $7.6B |
| Share price | $140.58 | $66.53 |
| Change, 1 year | −42.8% | 8.9% |
| Change, 5 years | −41.7% | −40.5% |
| Beta (5Y) | 1.16 | 1.10 |
| Employees | 15K | 13K |
| StockData Score | ||
| Total score | 10 | 16 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 2 | 6 (better) |
| Valuation | ||
| P/E | 312× | 12.2× (better) |
| P/S | 2.7× | 0.8× (better) |
| P/B | 1.4× | 1.2× (better) |
| EV/EBITDA | 22.4× | – |
| P/FCF | 27.0× | 16.2× (better) |
| FCF yield | 3.7% | 6.2% (better) |
| Fair value | $95.49 | $87.53 |
| Margin of safety | −47.2% | 24.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 3.3% (better) | 0.27% |
| Revenue growth, 5Y average | −9.3% | 0.65% (better) |
| Net income growth (TTM) | – | −13.3% |
| EPS growth (TTM) | – | −12.3% |
| EPS growth, 5Y average | – | 3.2% |
| Profitability | ||
| Gross margin | 35.1% (better) | 20.6% |
| Net margin | 0.79% | 6.9% (better) |
| FCF margin | 10.0% (better) | 5.2% |
| Return on equity | 0.30% | 10.4% (better) |
| Financial health | ||
| Debt / equity | 0.23 (better) | 0.83 |
| Net debt / EBITDA | 1.52 | – |
| Current ratio | 2.43 (better) | 1.57 |
| Altman Z-score | 0.46 | 2.15 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | 5.1% (better) |
| Payout ratio | 758% | 61.1% |
| Years of dividend growth | 0 | 16 (better) |
| Dividend growth, 5Y average | 3.6% | 4.5% (better) |
| Buyback yield | −0.71% | – |
| Shareholder yield | 1.00% | 5.1% (better) |
| Ownership | ||
| Held by institutions | 73.7% | 94.1% |
| Held by insiders | 0.95% | 0.83% |
| Insider net buying, 12 months | −$607K | −$366K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 3.8% | 5.9% |
Go deeper
- DD stock overview
- DD income statement
- DD valuation and score
- EMN stock overview
- EMN income statement
- EMN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.